Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Ultra Semiconductors (USD) vs Veeva Systems (VEEV) Price & Performance

ProShares Ultra SemiconductorsTrade
Veeva SystemsTrade

Price performance (Past 24H)

Key statistics

ProShares Ultra Semiconductors vs Veeva Systems — how do they compare? ProShares Ultra Semiconductors trades at $89.16, while Veeva Systems trades at $260.88 (market cap $42.88B). Which is the better fit depends on your goals.

USDVEEV
Sector
Leveraged / InverseTechnology
52-Week High
$113.53$306.22
52-Week Low
$43.19$151.43
Market Cap
$42.88B
Enterprise Value
$35.79B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Ultra Semiconductors

USD stock trades at $89.70, up 1.01% with bullish technical signals from moving averages. The company announced a dividend of $0.14 per share scheduled for June 2026. Technical indicators show strong support at $88 and resistance at $92, with RSI levels in neutral territory suggesting balanced momentum.

The stock shows technical strength but lacks current fundamental data for comprehensive valuation. The upcoming dividend provides income appeal, though investors face uncertainty without recent financial metrics. Market sentiment appears cautiously optimistic given the technical setup and corporate action.

Veeva Systems

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

About ProShares Ultra Semiconductors

USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.

Read more on USD

About Veeva Systems

Veeva Systems provides cloud software, data, and services for the life sciences industry. Its applications support functions across clinical research, regulatory operations, quality, safety, and commercial teams.

Read more on VEEV